Citable company snapshot
Thermo Fisher Scientific's latest SEC-sourced 2026-06-27 period shows $11.99B in revenue and $1.74B in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 27, 2026 | $11.99B | $11.01B | +9.0% |
| Gross Profit | Dec 31, 2019 | $3.04B | $2.76B | +9.8% |
| Operating Income | Jun 27, 2026 | $2.09B | $1.86B | +12.0% |
| Net Income | Jun 27, 2026 | $1.74B | $1.65B | +5.1% |
| Operating Cash Flow (computed) | Jun 27, 2026 | $2.13B | $1.19B | +78.3% |
| Free Cash Flow (computed) | Jun 27, 2026 | $1.68B | $816.00M | +105.3% |
Source: SEC EDGAR financial statements; period Jun 27, 2026; filed Jul 31, 2026; accession 0000097745-26-000144.
TMO company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.